Page 23 - EFH 222

10. Constable L, Davidson T, Breeman S, Cotton S, McDonald A, Wileman S, et al. How to deal with a temporary suspension and restarting your trial: our experiences and lessons learnt. Trials. 2020; 21(1): 765 \\\\\\\[DOI: 10.1186/s13063-020-04705-4\\\\\\\] \\\\\\\[PMID: 32891161; PMCID: PMC7474317\\\\\\\]. 11. Lorusso D, Ray-Coquard I, Oaknin A, Banerjee S. Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? ESMO Open. 2020; 5(5): e000924 \\\\\\\[DOI: 10.1136/ esmoopen-2020-000924\\\\\\\] \\\\\\\[PMID: 33051193; PMCID: PMC7554405\\\\\\\]. 12. Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, et al. Early Impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020; 16(7): 417-421 \\\\\\\[DOI: 10.1200/ OP.20.00275\\\\\\\] \\\\\\\[Epub 2020 May 12. PMID: 32396491\\\\\\\]. 13. Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov. 2020; 19(6): 376-377 \\\\\\\[DOI: 10.1038/d41573-020- 00093-1\\\\\\\] \\\\\\\[PMID: 32424343\\\\\\\]. 14. EMA. Guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic. Version 4, 04/0272021 \\\\\\\[consultado el 30 de agosto de 2021\\\\\\\]. Disponible en: https://ec. europa.eu/health/sites/default/files/files/eudralex/vol-10/ guidanceclinicaltrials_covid19_en.pdf 15. Food and Drug Administration (FDA). FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency: guidance for industry, investigators, especial Investigación clínica en tiempos de pandemia and institutional review boards. Docket number: FDA-2020-D-1106. March 2020 \\\\\\\[actualizado el 16 de abril de 2020) \\\\\\\[consultado el 30 de agosto de 2021\\\\\\\]. Disponible en: https://www.fda.gov/regulatory-information/ search-fda- guidance-documents/fda-guidance-conduct-clinical-trials- medical-products-during-covid-19-public-health-emergency 16. Pérez T, Pérez RL, Roman J. Conducting clinical research in the era of covid-19. Am J Med Sci. 2020; 360(3): 213-215 \\\\\\\[DOI: 10.1016/j.amjms.2020.06.011\\\\\\\] \\\\\\\[Epub 2020 Jun 10. PMID: 32690272; PMCID: PMC7283065\\\\\\\]. 17. Fleming TR, Labriola D, Wittes J. Conducting clinical research during the COVID-19 pandemic: protecting scientific integrity. JAMA. 2020; 324(1): 33-34 \\\\\\\[DOI: 10.1001/jama.2020.9286\\\\\\\]. 18. AEMPS. Medidas excepcionales aplicables a los ensayos clínicos para gestionar los problemas derivados de la emergencia por COVID-19 \\\\\\\[consultado el 30 de agosto de 2021\\\\\\\]. Disponible en: https://www.aemps.gob.es/informa/notasinformativas/ medicamentosusohumano-3/2020-medicamentosusohumano-3/ medidas-excepcionales-aplicables-a-los-ensayos-clinicos- para-gestionar-los-problemas-derivados-de-la-emergencia- por-covid-19/ 19. Hasford J. Impact of the COVID-19 pandemic on clinical trials with drugs. Expert Opin Drug Saf. 2020; 19(11): 1.373-1.375 \\\\\\\[DOI: 10.1080/14740338.2020.1828861\\\\\\\] \\\\\\\[PMID: 32970481\\\\\\\]. 20. Registro Español de Ensayos Clínicos \\\\\\\[consultado el 4 de septiembre de 2021\\\\\\\]. Disponible en: https://reec.aemps.es/ reec/public/list.html el farmacéutico hospitales n.o 222 21